Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
33 current organizations shown on this profile
Board positions
33 supported by public sources, 0 supplied by the profile owner
Committee roles
3Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Joined board December 2022 and serves as Chair. Corporate transactions and securities partner at Thompson Hine LLP since 2010, leading Life Sciences practice. Advises biotech and pharmaceutical companies on financing, M&A, and licensing transactions. J.D. from George Washington University Law School.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

CDT Equity Inc.

2026-08-11 · current

Confirmed by public sourceView source

Director

ABEONA THERAPEUTICS INC.

2021-01-01 · current

Confirmed by public sourceView source

Director

CNS Pharmaceuticals, Inc.

Current · start date not disclosed

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

ABEONA THERAPEUTICS INC.

Open ABEONA THERAPEUTICS INC. profile →

Director at ABEONA THERAPEUTICS INC.

2021-01-01 → End not stated

current · source reported

Observed: 2026-09-25

ABEONA THERAPEUTIC…ABEONA THERAPEUTICS INC.CDT Equity Inc.CDT Equity Inc.CNS Pharmaceutical…CNS Pharmaceuticals, Inc.Faith L. Charles

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec ProxyPublic profile sourceSupports Director at CDT Equity Inc. (NASDAQ: CDTTW).Open sourceSource 2 · Sec Form OwnershipPublic profile sourceSupports Director at CNS Pharmaceuticals, Inc. (NASDAQ: CNSP).Open sourceSource 3 · Sec FilingABEO DEF 14A executive officersSupports Executive company, Executive title.Open sourceSource 4 · Sec FilingCDT 10-K executive officersSupports Executive company, Executive title.Open sourceSource 5 · Sec FilingCNSP DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Other Company Role, Technology background.Open sourceSource 6 · Sec FilingABEO DEF 14A director slateSupports Board role, Committee assignments.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:faith-l-charles
Record version
public-0

Published evidence records

11 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Open source

    sec proxy · Source published: Aug 11, 2026 · Retrieved: Sep 2, 2026

    Supports 1 claim
    • Professional Role: Director at CDT Equity Inc. · Claim reviewed: May 16, 2026

  2. Open source

    sec form ownership · Source published: May 18, 2026 · Retrieved: Aug 2, 2026

    Supports 1 claim
    • Professional Role: Director at CNS Pharmaceuticals, Inc. · Claim reviewed: May 16, 2026

  3. ABEO DEF 14A executive officers

    sec filing · Source published: Apr 27, 2026 · Retrieved: May 15, 2026

    Supports 2 claims
    • Executive company: Executive at ABEONA THERAPEUTICS INC. · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Director and Chair of Nominating and Corporate Governance Committee · Claim reviewed: May 15, 2026

  4. CDT 10-K executive officers

    sec filing · Source published: Apr 15, 2026 · Retrieved: May 16, 2026

    Supports 2 claims
    • Executive company: Executive at CDT Equity Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Director · Claim reviewed: May 16, 2026

  5. CNSP DEF 14A executive officers

    sec filing · Source published: Oct 24, 2025 · Retrieved: May 16, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at CNS Pharmaceuticals, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Director and Chair of the Board of Directors · Claim reviewed: May 16, 2026
    • Other Company Role: Faith L. Charles is also linked to Abeona Therapeutics, Inc.; Avenue Therapeutics, Inc. as Board Member. · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  6. CNSP DEF 14A director slate

    sec filing · Source published: Oct 24, 2025 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Chair · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Nominating/Governance, Audit, Compensation · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  7. ABEO DEF 14A director slate

    sec filing · Source published: Apr 9, 2025 · Retrieved: May 15, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Compensation, Nominating/Governance · Claim reviewed: May 15, 2026

  8. Open source

    sec proxy · Source published: Apr 9, 2025 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at ABEONA THERAPEUTICS INC. · Claim reviewed: May 16, 2026

  9. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of CDT Equity Inc. · Claim reviewed: May 16, 2026

  10. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of ABEONA THERAPEUTICS INC. · Claim reviewed: May 16, 2026

  11. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of CNS Pharmaceuticals, Inc. · Claim reviewed: May 16, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Board membership · Source reportedServes on the board of ABEONA THERAPEUTICS INC.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of CDT Equity Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of CNS Pharmaceuticals, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · Source reportedBoard role: Chair1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · Source reportedCommittee assignments: Nominating/Governance, Audit, Compensation1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · Source reportedCommittee assignments: Compensation, Nominating/Governance1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at ABEONA THERAPEUTICS INC.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive company · Source reportedExecutive at CDT Equity Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at CNS Pharmaceuticals, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Director1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Director and Chair of Nominating and Corporate Governance Committee1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive title · Source reportedExecutive title: Director and Chair of the Board of Directors1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Other Company Role · Source reportedFaith L. Charles is also linked to Abeona Therapeutics, Inc.; Avenue Therapeutics, Inc. as Board Member.1 source
Verification
Source reported
Confidence
70%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources11 records
  1. https://www.sec.gov/Archives/edgar/data/1896212/000149315226036998/formdef14a.htm

    Sec Proxy · Tier not stated · Reviewed Sep 2, 2026

    Supports: Director at CDT Equity Inc. (NASDAQ: CDTTW)

  2. https://www.sec.gov/Archives/edgar/data/1729427/000168316826004145/ownership.xml

    Sec Form Ownership · Tier not stated · Reviewed Aug 2, 2026

    Supports: Director at CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: Executive company · Executive title

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title

  5. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Other Company Role · Technology background

  6. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  7. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: Board role · Committee assignments

  8. https://www.sec.gov/Archives/edgar/data/318306/000164117225003411/formdef14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at ABEONA THERAPEUTICS INC. (NASDAQ: ABEO)

  9. https://www.sec.gov/Archives/edgar/data/1896212/000149315226036998/formdef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  10. https://www.sec.gov/Archives/edgar/data/318306/000164117225003411/formdef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  11. https://www.sec.gov/Archives/edgar/data/1729427/000168316826004145/ownership.xml

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership